|
시장보고서
상품코드
2087685
동물용 의약품 시장 : 제품 카테고리, 투여 경로, 유통 채널, 대상 동물, 적응증, 의료 현장별 - 시장 예측(2026-2032년)Veterinary Drug Market by Product Category, Route Of Administration, Distribution Channel, Animal Type, Disease Indication, Care Setting - Global Forecast 2026-2032 |
||||||
360iResearch
동물용 의약품 시장은 2032년까지 연평균 복합 성장률(CAGR) 8.70%로 803억 1,000만 달러에 달할 것으로 예측됩니다.
| 주요 시장 통계 | |
|---|---|
| 기준 연도 : 2025년 | 447억 8,000만 달러 |
| 추정 연도 : 2026년 | 485억 7,000만 달러 |
| 예측 연도 : 2032년 | 803억 1,000만 달러 |
| CAGR(%) | 8.70% |
동물용 의약품 시장 요약 보고서
동물용 의약품 시장은 동물의 건강, 식량 안보, 반려동물 관리, 그리고 ‘원 헬스(One Health)’ 정책의 중요한 축입니다. 수요는 가축, 가금류, 수산 양식, 말 및 반려동물의 의료적 필요에 의해 뒷받침되고 있는 반면, 미국 식품의약국(FDA) 수의학 센터, 미국 농무부 동식물검역국(USDA APHIS), 유럽의약품청(EMA), 그리고 각국 당국의 규제 감독이 제품의 품질, 안전성, 유효성 및 의약품 안전성 감시를 지속적으로 형성하고 있습니다.
동물용 의약품 업계의 혁신적인 변화
동물의 건강 관리가 사후 대응적인 치료에서 예방, 모니터링, 그리고 정밀의료로 전환됨에 따라, 동물용 의약품의 현황도 변화하고 있습니다. 미국에서는 남아 있던 의학적으로 중요한 동물용 일반의약품을 수의학적 감독 하에 두도록 한 FDA의 ‘업계 지침 제263호’, 유럽에서는 항생제 사용 관리를 강화한 ‘규정(EU) 2019/6’과 같은 규제에 따라, 책임 있는 처방과 적정 사용이 가속화되고 있습니다.
인공지능(AI)의 누적 영향
인공지능(AI)은 동물용 의약품의 밸류체인에 영향을 미치기 시작했으며, 단기적으로는 신약 개발, 표적 선정, 임상시험 설계, 의약품 안전성 모니터링, 진단 의사결정 지원 및 정밀 축산 의료 분야에서 가장 큰 영향이 예상됩니다. AI를 활용한 모델은 데이터 세트가 검증되었으며, 적용되는 데이터 보호, 품질 관리 및 수의학 관련 규정을 준수하고 있다는 전제 하에, 화합물 스크리닝, 실세계 데이터(REW) 분석, 이상반응 패턴 감지, 그리고 진단 데이터와 치료 프로토콜 간의 연계 지원을 할 수 있습니다.
주요 지역별 분석 : 아시아태평양, 북미, 라틴아메리카, 유럽, 중동 및 아프리카
아시아태평양은 중국, 인도, 일본, 한국, 호주 및 아세안(ASEAN) 시장에서 방대한 가축 사육 규모, 반려동물 사육의 확대, 활발한 수산 양식이 맞물려 있어 최우선 성장 지역으로 부상하고 있습니다. FAOSTAT 및 각국의 농업 데이터 세트는 가금류, 돼지, 젖소, 수산 양식 분야의 해당 지역 규모를 일관되게 보여주고 있으며, 질병 예방, 백신, 구충제 및 항감염제의 적정 사용이 수요의 핵심을 이루고 있습니다. 또한, 이 지역은 국경을 넘는 동물 질병으로 인한 반복적인 위협에 직면해 있으며, 이로 인해 감시, 생물안전, 수의용 생물제제 및 필수 의약품에 대한 규제된 접근이 전략적으로 그 중요성이 커지고 있습니다.
주요 그룹에 대한 인사이트: 아세안(ASEAN), GCC, EU, 브릭스(BRICS), G7, 나토(NATO)
아세안 시장은 가금류, 수산 양식 및 양돈 분야의 현대화 혜택을 누리고 있으며, 수요는 백신, 구충제, 생물보안 관련 치료제 및 승인된 항감염제에 집중되어 있습니다. 고밀도 사육 시스템에서는 질병 예방이 특히 중요하며, 각국의 항생제 내성 대책 계획에 따라 수의학적 감독과 책임 있는 사용에 대한 관심이 높아지고 있습니다. GCC 국가들은 식량 안보, 유제품 생산, 낙타 및 말의 건강, 그리고 규제된 수입 경로에 투자하고 있으며, 이를 통해 고품질 수의약품, 생물학적 제제, 진단 기반 치료, 그리고 콜드체인 유통의 기회가 창출되고 있습니다.
주요 동물용 의약품 시장의 주요 국가에 대한 인사이트
미국은 수의약품 분야의 혁신, 명확한 규제 체계, 반려동물용 치료제 분야에서 선도적인 위치를 차지하고 있으며, FDA CVM(식품의약국 동물용의약품센터)과 USDA APHIS(미국 농무부 동식물검역국)가 의약품과 생물학적 제제에 대해 각각 독자적인 감독을 수행하고 있습니다. 캐나다는 연방 정부의 동물용 의약품 심사 및 식품 안전 관리에 힘입어, 가축과 반려동물에 대한 수요가 활발한 성숙한 동물 보건 시스템을 갖추고 있습니다. 멕시코에서는 동물용 의약품의 사용이 가금류, 돼지, 소 및 국경을 넘는 단백질 무역과 밀접하게 연관되어 있어, 질병 관리와 잔류 기준 준수가 여전히 핵심 과제로 남아 있습니다. 브라질은 세계 유수의 쇠고기 및 가금류 수출국 중 하나이므로 전략적 시장이며, 질병 관리, 백신 접종, 구충제 사용, 그리고 수출 기준을 준수하는 잔류물 관리가 상업적으로 매우 중요합니다.
동물용 의약품 업계의 리더를 위한 실천적 제안
업계 리더는 항균제 적정 사용, 잔류 기준, 의약품 안전성 감시 의무 및 우수 제조 기준(GMP) 요건을 충족하고, 규제 대응이 잘 갖춰진 제품 포트폴리오를 우선시해야 합니다. 투자는 백신, 구충제, 피부과 분야, 통증 관리, 만성 질환 치료, 생식 건강, 그리고 임상적 필요성과 반려인 및 생산자의 지불 의향이 명확한 특정 동물군 전용 제제에 중점을 두어야 합니다.
조사 방법
본 조사 방법은 규제 당국, 수의사 협회, 정부 간 기구, 과학 문헌, 업계 데이터베이스 및 공개 정보를 바탕으로 한 2차 조사와 체계적인 시장 분석을 결합한 것입니다. 주요 정보 출처로는 FDA CVM, USDA APHIS, EMA, 각국의 수의 당국, WOAH, FAO, WHO, 코덱스 알리멘타리우스의 지침, 항생제 내성 대책 계획 및 동료 심사를 거친 동물 보건 연구 등이 포함됩니다.
결론
동물용 의약품 시장은 예방 중시, 규제 강화, 디지털화의 진전, 그리고 치료 성과 중시라는 방향으로 변화하고 있습니다. 과학적 신뢰성, 책임감 있는 항생제 사용, 안정적인 공급, 강력한 의약품 안전성 감시, 그리고 지역 맞춤형 상업화 전략을 모두 갖춘 기업이 이러한 성장을 포착하는 데 있어 가장 유리한 입장에 있습니다.
자주 묻는 질문
목차
제1장 서문
제2장 조사 방법
제3장 주요 요약
제4장 시장 개요
제5장 시장 인사이트
제6장 AI의 누적 영향, 2026년
제7장 동물용 의약품 시장 : 제품 카테고리별
제8장 동물용 의약품 시장 : 투여 경로별
제9장 동물용 의약품 시장 : 유통 채널별
제10장 동물용 의약품 시장 : 대상 동물별
제11장 동물용 의약품 시장 : 적응증별
제12장 동물용 의약품 시장 : 의료 환경별
제13장 동물용 의약품 시장 : 지역별
제14장 동물용 의약품 시장 : 그룹별
제15장 동물용 의약품 시장 : 국가별
제16장 경쟁 구도
제17장 기업 개요
LSH 26.07.22The Veterinary Drug Market is projected to grow by USD 80.31 billion at a CAGR of 8.70% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 44.78 billion |
| Estimated Year [2026] | USD 48.57 billion |
| Forecast Year [2032] | USD 80.31 billion |
| CAGR (%) | 8.70% |
Veterinary Drug Market Executive Summary
The veterinary drug market is a critical pillar of animal health, food security, companion animal care, and One Health policy. Demand is supported by the medical needs of livestock, poultry, aquaculture, equine, and companion animals, while regulatory oversight from agencies such as the U.S. FDA Center for Veterinary Medicine, USDA APHIS, the European Medicines Agency, and national authorities continues to shape product quality, safety, efficacy, and pharmacovigilance.
Growth in veterinary pharmaceuticals is being driven by the rising burden of infectious and parasitic diseases, higher pet health spending, expanding animal protein consumption, and the need to protect herd productivity. According to WOAH, animal diseases can affect livestock production, trade continuity, and public health, reinforcing the importance of approved veterinary medicines, vaccines, diagnostics-linked treatment, and responsible antimicrobial use. At the same time, the market is shifting toward preventive care, prescription parasiticides, targeted anti-infective stewardship, dermatology therapies, pain management, reproductive health products, and species-specific formulations that align with modern veterinary practice.
Transformative Shifts in the Veterinary Drug Landscape
The veterinary drug landscape is transforming as animal health moves from reactive treatment to prevention, surveillance, and precision care. Regulations such as FDA Guidance for Industry #263, which moved remaining over-the-counter medically important antimicrobials for animals under veterinary oversight in the United States, and Regulation (EU) 2019/6, which strengthened antimicrobial-use controls in Europe, are accelerating responsible prescribing and stewardship.
Manufacturers are also adapting to changes in distribution and care delivery. E-commerce, veterinary clinic networks, telehealth-supported prescribing where permitted, and direct relationships with producers are reshaping access to approved products. Across livestock and companion animal segments, the strongest positioning is shifting toward portfolios that combine clinical efficacy, regulatory compliance, residue management, ease of administration, cold-chain reliability, and measurable outcomes.
Cumulative Impact of Artificial Intelligence
Artificial intelligence is beginning to influence the veterinary drug value chain, with the highest near-term impact in drug discovery, target identification, clinical trial design, pharmacovigilance, diagnostic decision support, and precision livestock health. AI-enabled models can help screen compounds, analyze real-world evidence, detect adverse event patterns, and connect diagnostic data with treatment protocols, provided that datasets are validated and compliant with applicable data protection, quality management, and veterinary regulations.
In commercial practice, AI is strengthening disease surveillance through herd monitoring, wearable sensors, imaging tools, laboratory data, and production analytics. These capabilities support earlier intervention, better antimicrobial stewardship, improved inventory planning, and more consistent treatment decisions. The cumulative impact is not the replacement of veterinarians, but the creation of evidence-led workflows that help veterinarians, producers, and pet owners use veterinary drugs more responsibly and effectively.
Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa
Asia-Pacific is a high-priority growth region because China, India, Japan, South Korea, Australia, and ASEAN markets combine large livestock populations, expanding pet ownership, and active aquaculture production. FAOSTAT and national agricultural datasets consistently show the region's scale in poultry, swine, dairy, and aquaculture, making disease prevention, vaccines, parasiticides, and anti-infective stewardship central to demand. The region also faces recurring pressure from transboundary animal diseases, which increases the strategic importance of surveillance, biosecurity, veterinary biologics, and regulated access to essential medicines.
North America remains one of the most regulated and innovation-led veterinary drug markets, supported by strong companion animal spending, advanced livestock production, and defined oversight from FDA CVM, USDA APHIS, Health Canada, and state-level veterinary boards. Latin America, led by Brazil and Mexico, is closely tied to beef, poultry, swine, and export-oriented protein supply chains, where residue compliance, disease control, and herd health programs are essential to market access and productivity.
Europe is shaped by rigorous pharmacovigilance, antimicrobial controls, and sustainability requirements under EU and national frameworks, with Regulation (EU) 2019/6 reinforcing prudent use of veterinary medicinal products. The Middle East is expanding demand through food security investments, dairy and poultry modernization, camel and equine health, and companion animal care in urban centers. Africa presents long-term potential linked to livestock disease control, vaccine access, public-sector programs, and the need to reduce productivity losses associated with endemic and transboundary animal diseases, including those prioritized by WOAH and national veterinary services.
Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO
ASEAN markets are benefiting from poultry, aquaculture, and swine modernization, with demand concentrated in vaccines, parasiticides, biosecurity-linked therapies, and approved anti-infectives. Disease prevention is especially important in dense production systems, while national antimicrobial resistance action plans are increasing attention on veterinary oversight and responsible use. GCC countries are investing in food security, dairy production, camel and equine health, and regulated import pathways, creating opportunities for premium veterinary products, biologics, diagnostics-linked treatment, and cold-chain distribution.
The European Union remains a benchmark for veterinary drug regulation, particularly through Regulation (EU) 2019/6 and coordinated pharmacovigilance, which influence product authorization, antimicrobial stewardship, and post-market monitoring. BRICS markets combine major animal protein production, large companion animal populations, and diverse regulatory maturity, making local registration strategy, quality compliance, and manufacturing partnerships important. G7 markets are characterized by advanced veterinary infrastructure, high compliance expectations, and strong innovation adoption, while NATO countries overlap with many high-income regulated markets where supply resilience, biosecurity, and public health preparedness influence animal health policy and veterinary medicine availability.
Key Country Insights Across Major Veterinary Drug Markets
The United States leads in veterinary drug innovation, regulatory clarity, and companion animal therapeutics, with FDA CVM and USDA APHIS providing distinct oversight for drugs and biologics. Canada has a mature animal health system with strong livestock and companion animal demand, supported by federal veterinary drug review and food safety controls. Mexico links veterinary drug use to poultry, swine, cattle, and cross-border protein trade, where disease management and residue compliance remain central. Brazil is a strategic market because it is one of the world's most important beef and poultry exporters, making disease control, vaccination, parasiticide use, and export-compliant residue management commercially critical.
The United Kingdom, Germany, France, Italy, and Spain combine advanced veterinary services with strict European antimicrobial and pharmacovigilance standards, supporting demand for approved companion animal medicines, livestock vaccines, dermatology products, pain therapies, and preventive health solutions. Russia has substantial livestock production and domestic supply priorities, increasing the importance of local registration, supply continuity, and disease control. China and India are scale markets with significant livestock, aquaculture, and companion animal opportunities, though registration pathways, pricing dynamics, and local competition require careful market entry planning. Japan, Australia, and South Korea are high-compliance markets where premium companion animal therapies, vaccines, parasiticides, biosecurity, and evidence-based prescribing are especially important.
Actionable Recommendations for Veterinary Drug Industry Leaders
Industry leaders should prioritize regulatory-ready portfolios that align with antimicrobial stewardship, residue requirements, pharmacovigilance obligations, and Good Manufacturing Practice expectations. Investment should focus on vaccines, parasiticides, dermatology, pain management, chronic disease therapies, reproductive health, and species-specific formulations where clinical need and owner or producer willingness to pay are clear.
Companies should strengthen local registration expertise, diversify manufacturing and active ingredient sourcing, and build resilient cold-chain and clinic-facing distribution. Partnerships with veterinarians, producer groups, diagnostic providers, universities, and digital health providers can improve adoption, generate real-world evidence, and support differentiated value propositions in both livestock and companion animal segments. Leaders should also embed antimicrobial stewardship metrics, adverse event monitoring, and product education into commercialization to strengthen trust with regulators, veterinarians, producers, and pet owners.
Research Methodology
The research methodology combines secondary research from regulatory agencies, veterinary associations, intergovernmental organizations, scientific literature, trade databases, and public disclosures with structured market interpretation. Key sources include FDA CVM, USDA APHIS, EMA, national veterinary authorities, WOAH, FAO, WHO, Codex Alimentarius guidance, antimicrobial resistance action plans, and peer-reviewed animal health research.
Market assessment is developed through triangulation of regulatory developments, disease burden indicators, animal population trends, livestock production patterns, companion animal care dynamics, product approvals, distribution shifts, and expert-led validation. This approach supports data-backed insights without relying on unverified assumptions, unsupported market claims, market sizing, market share statements, or forecasting.
Conclusion
The veterinary drug market is becoming more prevention-driven, regulated, digitally enabled, and outcome-focused. Companies that combine scientific credibility, responsible antimicrobial practices, reliable supply, strong pharmacovigilance, and region-specific commercialization strategies are best positioned to capture growth.
As animal health becomes more closely linked to food security, public health, trade continuity, and sustainability, veterinary drug manufacturers must deliver products that meet clinical, regulatory, and economic expectations. The strongest opportunities will favor organizations that convert evidence, compliance, and innovation into trusted therapeutic value for veterinarians, producers, and pet owners.
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Definition
- 1.3. Market Segmentation & Coverage
- 1.4. Years Considered for the Study
- 1.5. Currency Considered for the Study
- 1.6. Language Considered for the Study
- 1.7. Key Stakeholders
2. Research Methodology
- 2.1. Introduction
- 2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
- 2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
- 2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
- 2.5. Data Triangulation
- 2.6. Research Outcomes
- 2.7. Research Assumptions
- 2.8. Research Limitations
3. Executive Summary
- 3.1. Introduction
- 3.2. CXO Perspective
- 3.3. Market Size & Growth Trends
- 3.4. Market Share Analysis, 2025
- 3.5. FPNV Positioning Matrix, 2025
- 3.6. New Revenue Opportunities
- 3.7. Next-Generation Business Models
- 3.8. Industry Roadmap
4. Market Overview
- 4.1. Introduction
- 4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
- 4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
- 4.4. Porter's Five Forces Analysis
- 4.5. PESTLE Analysis
- 4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
- 4.7. Go-to-Market Strategy
5. Market Insights
- 5.1. Consumer Insights & End-User Perspective
- 5.2. Consumer Experience Benchmarking
- 5.3. Opportunity Mapping
- 5.4. Distribution Channel Analysis
- 5.5. Pricing Trend Analysis
- 5.6. Regulatory Compliance & Standards Framework
- 5.7. ESG & Sustainability Analysis
- 5.8. Disruption & Risk Scenarios
- 5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Veterinary Drug Market, by Product Category
- 7.1. Anti-Infectives
- 7.1.1. Antibiotics
- 7.1.2. Antifungals
- 7.1.3. Antivirals
- 7.2. Anti-Inflammatories
- 7.3. Parasiticides
- 7.3.1. Ectoparasiticides
- 7.3.2. Endoparasiticides
- 7.3.3. Endectocides
- 7.4. Vaccines
- 7.4.1. Core Vaccines
- 7.4.2. Non-Core Vaccines
- 7.4.3. Autogenous Vaccines
- 7.5. Anti-Inflammatory & Pain Management
- 7.5.1. NSAIDs
- 7.5.2. Corticosteroids
- 7.5.3. Analgesics
- 7.6. Hormones & Reproductive Health
- 7.7. Dermatology
- 7.8. Gastrointestinal
- 7.8.1. Antiemetics
- 7.8.2. Antidiarrheals
8. Veterinary Drug Market, by Route Of Administration
- 8.1. Inhalation
- 8.2. Parenteral
- 8.2.1. Intramuscular
- 8.2.2. Subcutaneous
- 8.2.3. Intravenous
- 8.2.4. Intradermal
- 8.3. Oral
- 8.3.1. Tablets & Capsules
- 8.3.2. Oral Liquids
- 8.3.3. Chewables
- 8.3.4. Medicated Feed & Water
- 8.4. Topical
- 8.4.1. Creams & Ointments
- 8.4.2. Sprays
- 8.5. Ophthalmic
9. Veterinary Drug Market, by Distribution Channel
- 9.1. Online Pharmacies
- 9.2. Retail Pharmacies
- 9.3. Veterinary Hospitals
- 9.4. Feed & Farm Supply Stores
- 9.5. Government & Institutional Procurement
10. Veterinary Drug Market, by Animal Type
- 10.1. Companion Animals
- 10.1.1. Dogs
- 10.1.2. Cats
- 10.1.3. Small Mammals
- 10.1.3.1. Rabbits
- 10.1.3.2. Guinea Pigs
- 10.1.3.3. Ferrets
- 10.1.4. Birds
- 10.1.4.1. Psittacines
- 10.1.4.2. Passerines
- 10.1.5. Exotics
- 10.1.5.1. Reptiles
- 10.1.5.2. Amphibians
- 10.2. Livestock Animals
- 10.2.1. Cattle
- 10.2.1.1. Dairy Cattle
- 10.2.1.2. Beef Cattle
- 10.2.2. Swine
- 10.2.2.1. Breeding Swine
- 10.2.2.2. Finisher Swine
- 10.2.3. Poultry
- 10.2.3.1. Broilers
- 10.2.3.2. Layers
- 10.2.4. Small Ruminants
- 10.2.4.1. Sheep
- 10.2.4.2. Goats
- 10.2.5. Aquaculture
- 10.2.5.1. Freshwater
- 10.2.5.2. Marine
- 10.2.1. Cattle
- 10.3. Equines
- 10.3.1. Horses
- 10.3.2. Donkeys & Mules
- 10.4. Laboratory Animals
- 10.5. Zoo & Wildlife Animals
11. Veterinary Drug Market, by Disease Indication
- 11.1. Infectious Diseases
- 11.2. Dermatological Disorders
- 11.3. Respiratory Disorders
- 11.4. Gastrointestinal Disorders
- 11.5. Musculoskeletal Disorders
- 11.6. Reproductive Disorders
- 11.7. Neurological Disorders
- 11.8. Ophthalmic Disorders
12. Veterinary Drug Market, by Care Setting
- 12.1. Companion Animal Practice
- 12.2. Livestock Production Operations
- 12.3. Aquaculture Farms
- 12.4. Research Institutions
- 12.5. Shelters & Rescue Organizations
- 12.6. Zoos & Wildlife Centers
13. Veterinary Drug Market, by Region
- 13.1. Asia-Pacific
- 13.2. North America
- 13.3. Latin America
- 13.4. Europe
- 13.5. Middle East
- 13.6. Africa
14. Veterinary Drug Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
15. Veterinary Drug Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
16. Competitive Landscape
- 16.1. Market Concentration Analysis, 2025
- 16.1.1. Concentration Ratio (CR)
- 16.1.2. Herfindahl Hirschman Index (HHI)
- 16.2. Recent Developments & Impact Analysis, 2025
- 16.3. Product Portfolio Analysis, 2025
- 16.4. Benchmarking Analysis, 2025
17. Company Profiles
- 17.1. Zoetis Inc.
- 17.2. Merck & Co., Inc.
- 17.3. Boehringer Ingelheim International GmbH
- 17.4. Elanco Animal Health Incorporated
- 17.5. Ceva Sante Animale
- 17.6. Virbac S.A.
- 17.7. Dechra Pharmaceuticals PLC
- 17.8. Phibro Animal Health Corporation
- 17.9. Norbrook Group
- 17.10. Vetoquinol Group
- 17.11. Neogen Corporation
- 17.12. Chanelle Pharma
- 17.13. Aurora Pharmaceutical, Inc.
- 17.14. Biogenesis Bago S.A.
- 17.15. Biovac Ltd.
- 17.16. China Animal Husbandry Industry Co., Ltd.
- 17.17. ECO Animal Health Group PLC
- 17.18. Heska Corporation by Mars, Incorporated
- 17.19. Hester Biosciences Limited
- 17.20. Indian Immunologicals Ltd.
- 17.21. Intas Pharmaceuticals Ltd.
- 17.22. Laboratorio Drag Pharma Chile Invetec S.A.
- 17.23. Teknofarma S.r.l.
- 17.24. Vetpharma Animal Health S.L. by Insud Pharma S.L.U.
- 17.25. Zendal Group
